Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rexulti in Borderline Personality Disorder
NCT03418675Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
A Phase 2 trial of brexpiprazole in borderline personality disorder (BPD), sponsored by University of Chicago. Started Nov 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT03418675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418675.